Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
IANAL, but unless one has a method that is not based on published papers, a better business model may be the service model, rather than patent and protect.
-
I think it's really the issue when the analysis tool such as BWT are necessary in the personal genome era.
Leave a comment:
-
There's no doubt that this is a mine field, however the BWT based aligners could argue they're based primarily on the fm-index papers (which predate these patents) rather than the specific tweaks employed in these patents.
A complex mess though, and one which only serves to demonstrate why software patents are generally bad for science as a whole.
Leave a comment:
-
Alignment/assembly programs - Patent minefield
There are many programs to align short reads to a reference, and quite a few denovo assemblers as well. The terrific list here gives great links to many tools.
But when I see these nifty toys and pick them up to examine them, it's clear that there's a quietly deadly dangers in many, in fact probably all, of the tools.
Which of these tools are safe to use without fear of patent violations? From my experience in database tools, the patent mindfield is terrible. But it seems even worse in bioinformatics because the field is newer and therefore more of the basic infrastructure has been patented from the start.
The Celera assembler for example, is covered by multiple patents and it's clearly not legal to use their methods, even for academic non-profit use. The GPL license is not what I'm talking about, but the patents underlaying its function. I'm not saying people haven't used the assember, but that their use is likely a violation even if Celera hasn't persued it yet. Celera is also far from the only patent holder.
This applies to almost all of these tools. I doubt any one of them is free from patent restrictions. Even the awesome and elegant Bowtie is likely infringing multiple times, since about anything that uses the BWT to search on DNA sequences is patented.
How are people protecting themselves from this issue? Have patent holders like Celera offered licenses, or indemity, at least for noncommercial users?
How do the researchers of these algorithms defend themselves?
How could any company even think to commercialize such tools unless they have a huge portfolio of patents of their own to play mutual-assured-destruction faceoffs with?
I fear that the answers to these questions is that people have just ignored the issues for now and hope that none of the patent holders decides to start poking at their projects.Tags: None
Latest Articles
Collapse
-
by seqadmin
The field of immunogenetics explores how genetic variations influence immune responses and susceptibility to disease. In a recent SEQanswers webinar, Oscar Rodriguez, Ph.D., Postdoctoral Researcher at the University of Louisville, and Ruben Martínez Barricarte, Ph.D., Assistant Professor of Medicine at Vanderbilt University, shared recent advancements in immunogenetics. This article discusses their research on genetic variation in antibody loci, antibody production processes,...-
Channel: Articles
11-06-2024, 07:24 PM -
-
by seqadmin
Next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR) are essential techniques for investigating the genome, transcriptome, and epigenome. In many cases, choosing the appropriate technique is straightforward, but in others, it can be more challenging to determine the most effective option. A simple distinction is that smaller, more focused projects are typically better suited for qPCR, while larger, more complex datasets benefit from NGS. However,...-
Channel: Articles
10-18-2024, 07:11 AM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, 11-08-2024, 11:09 AM
|
0 responses
57 views
0 likes
|
Last Post
by seqadmin
11-08-2024, 11:09 AM
|
||
Started by seqadmin, 11-08-2024, 06:13 AM
|
0 responses
38 views
0 likes
|
Last Post
by seqadmin
11-08-2024, 06:13 AM
|
||
Started by seqadmin, 11-01-2024, 06:09 AM
|
0 responses
35 views
0 likes
|
Last Post
by seqadmin
11-01-2024, 06:09 AM
|
||
New Model Aims to Explain Polygenic Diseases by Connecting Genomic Mutations and Regulatory Networks
by seqadmin
Started by seqadmin, 10-30-2024, 05:31 AM
|
0 responses
23 views
0 likes
|
Last Post
by seqadmin
10-30-2024, 05:31 AM
|
Leave a comment: